Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) | Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director | 1.28M | -- | 1957 |
| Dr. Eric A. Rose M.D. | Chief Medical Officer & Executive Director | 1.07M | -- | 1951 |
| Mr. Andrew Chaponnel B.Com. | Interim Chief Finance Officer | -- | -- | -- |
| Mr. Peter T. Howard B.Sc., L.L.B., LLB (Hons) | General Counsel & Corporate Executive | -- | -- | 1968 |
| Dr. Paul J. Simmons BSc, Ph.D. | Scientific Advisor to the Chief Executive Officer | -- | -- | 1959 |
| Ms. Geraldine Storton B.Sc., M.B.A., MMS | Head of Regulatory Affairs & Quality Management | -- | -- | -- |
| Mr. Justin Horst B.S. | Head of Manufacturing | -- | -- | -- |
| Dr. Fiona See Ph.D. | Senior VP & Head of Translational Research | -- | -- | -- |
| Ms. Niva Sivakumar B.Com., L.L.B. | Joint Company Secretary | -- | -- | -- |
| Mr. Paul Hughes BPHARM | Joint Company Secretary | -- | -- | -- |
Mesoblast Limited
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 73
Description
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
Corporate Governance
Upcoming Events
February 26, 2025 at 12:00 AM UTC - March 3, 2025 at 12:00 AM UTC
Mesoblast Limited Earnings Date